We were able to compare the performance of NT-proBNP with clinical risk equations for cardiovascular and renal endpoints that were developed in comparable participant cohorts from the same centre, providing the most appropriate multivariate model for comparison, as highlighted by a recent systematic review on prognostic markers for CVD in type 2 diabetes [3]. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.